Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

Researchers have found in a new study that a significant association between psoriasis severity and apical periodontitis (AP) ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

Currently, all biologic treatments for psoriasis, including anti-tumour necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe.

In this article we will help you to know more about the infusion therapy, about its process, precautions to be taken care ...

Both are once-a-day treatments. For moderate to severe ... Side effects, front and centre Systemic biologics are better for cases of psoriasis that do not resolve with lower-potency topicals ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, ...